AbbVie (ABBV) Cash & Current Investments (2012 - 2026)

AbbVie (ABBV) has reported Cash & Current Investments for 15 consecutive years, with $6.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Current Investments rose 1.58% year-over-year to $6.6 billion in Q2 2026; TTM through Jun 2026 was $6.6 billion, a 1.58% increase from a year earlier, with the FY2025 full-year figure at $5.3 billion, down 5.36% from the prior year.
• Cash & Current Investments was $6.6 billion for Q2 2026 at AbbVie, down from $9.4 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $18.1 billion in Q1 2024 and troughed at $5.2 billion in Q1 2025.
• A 5-year average of $9.0 billion and a median of $8.2 billion in 2022 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments jumped 168.8% in 2024 and sank 71.35% in 2025, its largest moves.
• Over 5 years, Cash & Current Investments stood at $9.2 billion in 2022, then surged by 38.87% to $12.8 billion in 2023, then slumped by 56.66% to $5.6 billion in 2024, then slipped by 5.36% to $5.3 billion in 2025, then advanced by 24.96% to $6.6 billion in 2026.
• The last three Cash & Current Investments figures came in at $6.6 billion (Q2 2026), $9.4 billion (Q1 2026), and $5.3 billion (Q4 2025), per Business Quant data.